AF
RLMD icon

Amalgamated Financial’s Relmada Therapeutics RLMD Stock Holding History

Amalgamated Financial’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$96K Buy
+3,567
New +$73.8K ﹤0.01% 2165

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Amalgamated Financial's RLMD Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Relmada Therapeutics (RLMD) in Q1 2022: 3,567 shares worth $96K. The stake represents ﹤0.01% of the portfolio and ranks #2165 among its holdings.

113 funds tracked by Wall St. Rank hold RLMD as of Q1 2022.

  • Amalgamated Financial held 3,567 shares of Relmada Therapeutics worth $96K as of Q1 2022.
  • Relmada Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Relmada Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2165 holding.
  • 113 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.